Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Impacts of IPSS-m and conditioning intensity in allogeneic hematopoietic cell transplant for patients with myelodysplasia neoplasms

View Full Paper
Ask AI
Bookmark
Share

Authors

HCHongru ChenUNSW SydneyMHMinli HuZhongshan People's HospitalCZChupeng ZhangSouthern Medical University

Discussion

Loading...

Member takes

Overview

Retrospective study reveals risk factors affecting overall survival in patients with myelodysplastic syndrome after bone marrow transplant, indicating graft versus host disease severity matters.

Key Points

  • This research investigates the prognostic value of IPSS-M scores and conditioning intensity in myelodysplastic syndrome patients undergoing allogeneic hematopoietic cell transplantation.
  • Retrospective multicenter study of MDS patients aged ≥ 14 years receiving their first allo-HCT from 2019 to 2025.
  • Enrolled patients received either myeloablative or reduced intensity conditioning before transplant.
  • Outcomes assessed included overall survival, acute and chronic graft versus host disease incidences, and relapse rates.
  • 3-year overall survival was 77.8%, with relapses at 18.6% and non-relapse mortality at 11.4%.
  • IPSS-M very high subgroup showed inferior survival rates compared to lower-risk patients, with 59% OS vs 82%.
  • Graft versus host disease incidences were recorded at 22.4% for grade II–IV and 14.1% for grade III-IV by day 100.

Cite This Study

Chen et al. (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d75ahttps://doi.org/10.1182/blood-2025-1062
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Prognostic impact of pre-transplant IPSS-m risk downstaging in Myelodysplastic Syndromes2025
  2. 2Impact of pre-allogeneic stem cell transplantation (SCT) disease characteristics, therapy, and response on post-SCT outcomes in higher risk myelodysplastic syndromes2025 · 1 citations
  3. 3IPSS-M downstaging before transplantation does not improve the prognosis of patients with myelodysplastic neoplasms2026 · 1 citations
  4. 4Upfront vs posttherapy allogeneic stem cell transplantation for high-risk myelodysplastic syndrome – a real-world analysis in the era of molecular risk stratification2025
  5. 5Conditioning intensity in myelodysplastic patients aged ≥ 50 years undergoing allogeneic hematopoietic cell transplantation (allo-HCT): a study on behalf of the chronic malignancies working party of the EBMT2025 · 2 citations